Difference between revisions of "EYE5:Volunteer Assignments and Opportunities"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[checked revision][checked revision]
(Created page with "Welcome! For assignments, please see the "Author" column below (highlighted blue). If empty (no name is present), please volunteer to create content for that disease! To vo...")
 
Line 19: Line 19:
 
!'''Notes'''
 
!'''Notes'''
 
|- |Usual ductal hyperplasia||Disease||
 
|- |Usual ductal hyperplasia||Disease||
−
|Usual Ductal Hyperplasia
+
|
 
|Disease
 
|Disease
 
|
 
|
Line 27: Line 27:
 
|
 
|
 
|-
 
|-
−
|Columnar Cell Lesions, Including Flat Epithelial Atypia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 36: Line 36:
 
|
 
|
 
|-
 
|-
−
|Atypical Ductal Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 45: Line 45:
 
|
 
|
 
|-
 
|-
−
|Sclerosing Adenosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 54: Line 54:
 
|
 
|
 
|-
 
|-
−
|Apocrine Adenosis and Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 63: Line 63:
 
|
 
|
 
|-
 
|-
−
|Microglandular Adenosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 72: Line 72:
 
|
 
|
 
|-
 
|-
−
|Radial Scar/Complex Sclerosing Lesion||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 81: Line 81:
 
|
 
|
 
|-
 
|-
−
|Tubular Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 90: Line 90:
 
|
 
|
 
|-
 
|-
−
|Lactating Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 99: Line 99:
 
|
 
|
 
|-
 
|-
−
|Ductal Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 108: Line 108:
 
|
 
|
 
|-
 
|-
−
|Pleomorphic Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 117: Line 117:
 
|
 
|
 
|-
 
|-
−
|Adenomyoepithelioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 126: Line 126:
 
|
 
|
 
|-
 
|-
−
|Malignant Adenomyoepithelioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 135: Line 135:
 
|
 
|
 
|-
 
|-
−
|Intraductal Papilloma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 144: Line 144:
 
|
 
|
 
|-
 
|-
−
|Papillary Ductal Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 153: Line 153:
 
|
 
|
 
|-
 
|-
−
|Encapsulated Papillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 162: Line 162:
 
|
 
|
 
|-
 
|-
−
|Solid Papillary Carcinoma (In Situ and Invasive)||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 171: Line 171:
 
|
 
|
 
|-
 
|-
−
|Invasive Papillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 180: Line 180:
 
|
 
|
 
|-
 
|-
−
|Atypical Lobular Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 189: Line 189:
 
|
 
|
 
|-
 
|-
−
|Lobular Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 198: Line 198:
 
|
 
|
 
|-
 
|-
−
|Ductal Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 207: Line 207:
 
|
 
|
 
|-
 
|-
−
|Invasive Breast Carcinoma of No Special Type||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 216: Line 216:
 
|
 
|
 
|-
 
|-
−
|Microinvasive Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 225: Line 225:
 
|
 
|
 
|-
 
|-
−
|Invasive lobular Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 234: Line 234:
 
|
 
|
 
|-
 
|-
−
|Tubular Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 243: Line 243:
 
|
 
|
 
|-
 
|-
−
|Cribriform Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 252: Line 252:
 
|
 
|
 
|-
 
|-
−
|Mucinous Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 261: Line 261:
 
|
 
|
 
|-
 
|-
−
|Mucinous Cystadenocarcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 270: Line 270:
 
|
 
|
 
|-
 
|-
−
|Invasive Micropapillary Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 279: Line 279:
 
|
 
|
 
|-
 
|-
−
|Carcinoma with Apocrine Differentiation||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 288: Line 288:
 
|
 
|
 
|-
 
|-
−
|Metaplastic Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 297: Line 297:
 
|
 
|
 
|-
 
|-
−
|Acinic Cell Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 306: Line 306:
 
|
 
|
 
|-
 
|-
−
|Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach / Jun Liao
+
| ||Disease||
−
|10/12/02022
+
|
−
|11/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 +
|
 
|
 
|
−
|Hui Chen / Katherine Geiersbach
 
−
|12/6/2023
 
−
|2021 template added
 
 
|-
 
|-
−
|Secretory Carcinoma||Disease||Hui Chen / Morteza Seifi
+
| ||Disease||
−
|10/12/2022
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
 
 
|
 
|
−
|2021 template added
 
 
|-
 
|-
−
|Mucoepidermoid Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 333: Line 333:
 
|
 
|
 
|-
 
|-
−
|Polymorphous Adenocarcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 342: Line 342:
 
|
 
|
 
|-
 
|-
−
|Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
+
| ||Disease||
−
|8/11/2023
+
|
−
|10/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
 
 
|
 
|
−
|2021 template added
 
 
|-
 
|-
−
|Neuroendocrine Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 360: Line 360:
 
|
 
|
 
|-
 
|-
−
|Neuroendocrine Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 369: Line 369:
 
|
 
|
 
|-
 
|-
−
|Hamartoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 378: Line 378:
 
|
 
|
 
|-
 
|-
−
|Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
−
|2021 template added
 
 
|-
 
|-
−
|Phyllodes Tumour||Disease||H. Evin Gulbahce / Patricija Zot / Emilie Lalonde / Katherine Geiersbach
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|PENDING
+
|
 +
|
 
|
 
|
 
|
 
|
 
|
 
|
−
|2021 template added
 
 
|-
 
|-
−
|Syringomatous Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 405: Line 405:
 
|
 
|
 
|-
 
|-
−
|Nipple Adenoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 414: Line 414:
 
|
 
|
 
|-
 
|-
−
|Paget disease of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 423: Line 423:
 
|
 
|
 
|-
 
|-
−
|Haemangioma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 432: Line 432:
 
|
 
|
 
|-
 
|-
−
|Angiomatosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 441: Line 441:
 
|
 
|
 
|-
 
|-
−
|Atypical Vascular Lesions||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 450: Line 450:
 
|
 
|
 
|-
 
|-
−
|Postradiation Angiosarcoma of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 459: Line 459:
 
|
 
|
 
|-
 
|-
−
|Primary Angiosarcoma of the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 468: Line 468:
 
|
 
|
 
|-
 
|-
−
|Nodular Fasciitis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 477: Line 477:
 
|
 
|
 
|-
 
|-
−
|Myofibroblastoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 486: Line 486:
 
|
 
|
 
|-
 
|-
−
|Desmoid Fibromatosis||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 495: Line 495:
 
|
 
|
 
|-
 
|-
−
|Inflammatory Myofibroblastic Tumour||Disease||Yajuan Liu
+
| ||Disease||
−
|8/11/2023
+
|
−
|11/11/2023
+
|
−
|COMPLETE
+
|
 +
|
 +
|
 +
|
 
|
 
|
−
|Katherine Geiersbach
 
−
|12/6/2023
 
−
|2021 template added
 
 
|-
 
|-
−
|Schwannoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 513: Line 513:
 
|
 
|
 
|-
 
|-
−
|Neurofibroma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 522: Line 522:
 
|
 
|
 
|-
 
|-
−
|Granular Cell Tumour||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 531: Line 531:
 
|
 
|
 
|-
 
|-
−
|Leiomyoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 540: Line 540:
 
|
 
|
 
|-
 
|-
−
|Leiomyosarcoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 549: Line 549:
 
|
 
|
 
|-
 
|-
−
|Lipoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 558: Line 558:
 
|
 
|
 
|-
 
|-
−
|Angiolipoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 567: Line 567:
 
|
 
|
 
|-
 
|-
−
|Liposarcoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 576: Line 576:
 
|
 
|
 
|-
 
|-
−
|Pseudoangiomatous Stromal Hyperplasia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 585: Line 585:
 
|
 
|
 
|-
 
|-
−
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 594: Line 594:
 
|
 
|
 
|-
 
|-
−
|Follicular Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 603: Line 603:
 
|
 
|
 
|-
 
|-
−
|Diffuse Large B-cell Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 612: Line 612:
 
|
 
|
 
|-
 
|-
−
|Burkitt Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 621: Line 621:
 
|
 
|
 
|-
 
|-
−
|Breast Implant-Associated Anaplastic Large Cell Lymphoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 630: Line 630:
 
|
 
|
 
|-
 
|-
−
|Gynaecomastia||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 639: Line 639:
 
|
 
|
 
|-
 
|-
−
|Carcinoma In Situ||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 648: Line 648:
 
|
 
|
 
|-
 
|-
−
|Invasive Carcinoma||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 657: Line 657:
 
|
 
|
 
|-
 
|-
−
|Metastases to the Breast||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 666: Line 666:
 
|
 
|
 
|-
 
|-
−
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin / Katherine Geiersbach
+
| ||Disease||
−
|12/6/2023
+
|
−
|3/6/2024
+
|
 
|
 
|
 
|
 
|
Line 675: Line 675:
 
|
 
|
 
|-
 
|-
−
|Cowden Syndrome||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 684: Line 684:
 
|
 
|
 
|-
 
|-
−
|Ataxia-Telangiectasia||Disease||Evin Gulbahce / Katherine Geiersbach
+
| ||Disease||
−
|12/11/2023
+
|
−
|3/11/2024
+
|
 +
|
 
|
 
|
 
|
 
|
−
|Katherine Geiersbach
 
 
|
 
|
 
|
 
|
 
|-
 
|-
−
|Li-Fraumeni Syndrome, TP53-Associated||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 702: Line 702:
 
|
 
|
 
|-
 
|-
−
|Li-Fraumeni Syndrome, CHEK2-Associated||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 711: Line 711:
 
|
 
|
 
|-
 
|-
−
|CDH1-Associated Breast Cancer||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 720: Line 720:
 
|
 
|
 
|-
 
|-
−
|PALB2-Associated Cancers||Disease||Constance Albarracin / Katherine Geiersbach
+
| ||Disease||
−
|12/8/2023
+
|
−
|3/8/2024
+
|
 
|
 
|
 
|
 
|
Line 729: Line 729:
 
|
 
|
 
|-
 
|-
−
|Peutz-Jeghers Syndrome||Disease||
+
| ||Disease||
 
|
 
|
 
|
 
|
Line 738: Line 738:
 
|
 
|
 
|-
 
|-
−
|Neurofibromatosis Type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
+
| ||Disease||
 +
|
 
|
 
|
 
|
 
|
Line 745: Line 746:
 
|
 
|
 
|
 
|
−
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
 
 
|-
 
|-
−
|Polygenic Component of Breast Cancer Susceptibility
+
|
 
|Disease
 
|Disease
 
|
 
|

Revision as of 13:02, 24 December 2023

Welcome!

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!

To volunteer, please [Contact us] with your page of interest.


WHO Classification of Eye and Orbit Tumours (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease
Disease


Retrieved from "https://ccga.io/index.php?title=EYE5:Volunteer_Assignments_and_Opportunities&oldid=14030"